secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001185185-22-000734
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment
-------------------------------------------------------------------------------

- Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.
- Aims to reduce side effects of hydantoin anticonvulsants like phenobarbital by lowering dosing.
- Company plans to pursue veterinarian pathway with observational studies and clinical trials for dogs and cats.
- Approximately 50 million people worldwide affected by epilepsy; ~3.8 million dogs in U.S. suffer from seizures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000734/0001185185-22-000734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000734/indiaglob20220608_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-22-000734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer